TP53 and central nervous system cancer: In vivo and in vitro experiments have shown that in gliomas with mutations in human TP53 (tumor protein P53), zDHHC5 mediates enhancer of EZH2 (zeste homolog 2) palmitoylation, leading to an altered phosphorylation state of EZH2 that drives glioma development (Gong et al., 2023).